April 20, 2014 11:02 AM ET


Company Overview of LeukoSite, Inc.

Company Overview

As of December 22, 1999, LeukoSite, Inc. was acquired by Millennium Pharmaceuticals Inc. LeukoSite, Inc. developed small molecule and monoclonal antibody therapeutics for inflammatory, autoimmune, and viral diseases, as well as for cancer applications, as of September 30, 1999. Its products included CAMPATH™ for the treatment of chronic lymphocytic leukemia, LDP-02 for the treatment of inflammatory bowel disease, LDP-01 for the prevention of post-ischemic reperfusion injury, and LDP-977 for the treatment of bronchial asthma. The company also had nine partner-funded research and discovery programs based on the selective blockade of specific chemokine, chemokine receptor, or integrin controlle...

215 First Street

Cambridge, MA 02142

United States



Key Executives for LeukoSite, Inc.

LeukoSite, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Sagres Discovery, Inc. United States
DNAtriX, Inc. United States
FORMA Therapeutics, Inc. United States
Expression Genetics, Inc. United States
Chondrial Therapeutics LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LeukoSite, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.